Erratum: Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors (Cell Reports (2021) 35(1), (S2211124721002588), (10.1016/j.celrep.2021.108944))

Roman V. Uzhachenko; Vijaya Bharti; Zhufeng Ouyang; Ashlyn Blevins; Stacey Mont; Nabil Saleh; Hunter A. Lawrence; Chengli Shen; Sheau Chiann Chen; Gregory D. Ayers; David G. DeNardo; Carlos Arteaga; Ann Richmond; Anna E. Vilgelm

doi:10.1016/j.celrep.2021.109271

Erratum: Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors (Cell Reports (2021) 35(1), (S2211124721002588), (10.1016/j.celrep.2021.108944))

Roman V. Uzhachenko, Vijaya Bharti, Zhufeng Ouyang, Ashlyn Blevins, Stacey Mont, Nabil Saleh, Hunter A. Lawrence, Chengli Shen, Sheau Chiann Chen, Gregory D. Ayers, David G. DeNardo, Carlos Arteaga, Ann Richmond, Anna E. Vilgelm

Research output: Contribution to journal › Comment/debate › peer-review

6 Scopus citations

Abstract

(Cell Reports 35, 108944-1–16.e1–e6; April 6, 2021) Carlos Arteaga receives or has received research grants from Pfizer, Lilly, and Takeda; holds minor stock options in Provista; serves or has served in an advisory role to Novartis, Merck, Lilly, Daiichi Sankyo, Taiho Oncology, OrigiMed, Puma Biotechnology, Immunomedics, AstraZeneca, Arvinas, and Sanofi; and reports scientific advisory board remuneration from the Susan G. Komen Foundation. None of these relationships are relevant to the work published in this manuscript. This information was inadvertently omitted during the preparation of the manuscript but now appears with the article online. The authors regret this error.

Original language	English (US)
Article number	109271
Journal	Cell Reports
Volume	35
Issue number	12
DOIs	https://doi.org/10.1016/j.celrep.2021.109271
State	Published - Jun 22 2021

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1016/j.celrep.2021.109271

Cite this

Uzhachenko, R. V., Bharti, V., Ouyang, Z., Blevins, A., Mont, S., Saleh, N., Lawrence, H. A., Shen, C., Chen, S. C., Ayers, G. D., DeNardo, D. G., Arteaga, C., Richmond, A., & Vilgelm, A. E. (2021). Erratum: Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors (Cell Reports (2021) 35(1), (S2211124721002588), (10.1016/j.celrep.2021.108944)). Cell Reports, 35(12), Article 109271. https://doi.org/10.1016/j.celrep.2021.109271

Erratum: Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors (Cell Reports (2021) 35(1), (S2211124721002588), (10.1016/j.celrep.2021.108944)). / Uzhachenko, Roman V.; Bharti, Vijaya; Ouyang, Zhufeng et al.
In: Cell Reports, Vol. 35, No. 12, 109271, 22.06.2021.

Research output: Contribution to journal › Comment/debate › peer-review

Uzhachenko, RV, Bharti, V, Ouyang, Z, Blevins, A, Mont, S, Saleh, N, Lawrence, HA, Shen, C, Chen, SC, Ayers, GD, DeNardo, DG, Arteaga, C, Richmond, A & Vilgelm, AE 2021, 'Erratum: Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors (Cell Reports (2021) 35(1), (S2211124721002588), (10.1016/j.celrep.2021.108944))', Cell Reports, vol. 35, no. 12, 109271. https://doi.org/10.1016/j.celrep.2021.109271

@article{0943a126d67b4ab5b3eea6c164029a86,

title = "Erratum: Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors (Cell Reports (2021) 35(1), (S2211124721002588), (10.1016/j.celrep.2021.108944))",

abstract = "(Cell Reports 35, 108944-1–16.e1–e6; April 6, 2021) Carlos Arteaga receives or has received research grants from Pfizer, Lilly, and Takeda; holds minor stock options in Provista; serves or has served in an advisory role to Novartis, Merck, Lilly, Daiichi Sankyo, Taiho Oncology, OrigiMed, Puma Biotechnology, Immunomedics, AstraZeneca, Arvinas, and Sanofi; and reports scientific advisory board remuneration from the Susan G. Komen Foundation. None of these relationships are relevant to the work published in this manuscript. This information was inadvertently omitted during the preparation of the manuscript but now appears with the article online. The authors regret this error.",

author = "Uzhachenko, {Roman V.} and Vijaya Bharti and Zhufeng Ouyang and Ashlyn Blevins and Stacey Mont and Nabil Saleh and Lawrence, {Hunter A.} and Chengli Shen and Chen, {Sheau Chiann} and Ayers, {Gregory D.} and DeNardo, {David G.} and Carlos Arteaga and Ann Richmond and Vilgelm, {Anna E.}",

note = "Publisher Copyright: {\textcopyright} 2021",

year = "2021",

month = jun,

day = "22",

doi = "10.1016/j.celrep.2021.109271",

language = "English (US)",

volume = "35",

journal = "Cell Reports",

issn = "2211-1247",

publisher = "Cell Press",

number = "12",

}

TY - JOUR

T1 - Erratum

T2 - Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors (Cell Reports (2021) 35(1), (S2211124721002588), (10.1016/j.celrep.2021.108944))

AU - Uzhachenko, Roman V.

AU - Bharti, Vijaya

AU - Ouyang, Zhufeng

AU - Blevins, Ashlyn

AU - Mont, Stacey

AU - Saleh, Nabil

AU - Lawrence, Hunter A.

AU - Shen, Chengli

AU - Chen, Sheau Chiann

AU - Ayers, Gregory D.

AU - DeNardo, David G.

AU - Arteaga, Carlos

AU - Richmond, Ann

AU - Vilgelm, Anna E.

PY - 2021/6/22

Y1 - 2021/6/22

N2 - (Cell Reports 35, 108944-1–16.e1–e6; April 6, 2021) Carlos Arteaga receives or has received research grants from Pfizer, Lilly, and Takeda; holds minor stock options in Provista; serves or has served in an advisory role to Novartis, Merck, Lilly, Daiichi Sankyo, Taiho Oncology, OrigiMed, Puma Biotechnology, Immunomedics, AstraZeneca, Arvinas, and Sanofi; and reports scientific advisory board remuneration from the Susan G. Komen Foundation. None of these relationships are relevant to the work published in this manuscript. This information was inadvertently omitted during the preparation of the manuscript but now appears with the article online. The authors regret this error.

AB - (Cell Reports 35, 108944-1–16.e1–e6; April 6, 2021) Carlos Arteaga receives or has received research grants from Pfizer, Lilly, and Takeda; holds minor stock options in Provista; serves or has served in an advisory role to Novartis, Merck, Lilly, Daiichi Sankyo, Taiho Oncology, OrigiMed, Puma Biotechnology, Immunomedics, AstraZeneca, Arvinas, and Sanofi; and reports scientific advisory board remuneration from the Susan G. Komen Foundation. None of these relationships are relevant to the work published in this manuscript. This information was inadvertently omitted during the preparation of the manuscript but now appears with the article online. The authors regret this error.

UR - http://www.scopus.com/inward/record.url?scp=85108264951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85108264951&partnerID=8YFLogxK

U2 - 10.1016/j.celrep.2021.109271

DO - 10.1016/j.celrep.2021.109271

M3 - Comment/debate

C2 - 34161761

AN - SCOPUS:85108264951

SN - 2211-1247

VL - 35

JO - Cell Reports

JF - Cell Reports

IS - 12

M1 - 109271

ER -

Erratum: Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors (Cell Reports (2021) 35(1), (S2211124721002588), (10.1016/j.celrep.2021.108944))

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this